Design of potent, non-toxic anticancer peptides based on the structure of the antimicrobial peptide, temporin-1CEa

Archives of Pharmacal Research

Volumn 36, Issue 11, 2013, Pages 1302-1310

  Yang, Qing Zhu ^a   Wang, Che ^a   Lang, Lei ^a   Zhou, Yang ^a   Wang, He ^a   Shang, De Jing ^a  

^a LIAONING NORMAL UNIVERSITY   (China)

Author keywords

Analog; Anticancer activity; Cationicity; Hemolysis; Hydrophobicity; Temporin 1CEa

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; POLYPEPTIDE ANTIBIOTIC AGENT; TEMPORIN 1CEA; UNCLASSIFIED DRUG;

ALPHA HELIX; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; PEPTIDE SYNTHESIS; PROTEIN STRUCTURE;

ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HEMOLYSIS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84888132582     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0112-8     Document Type: Article

References (29)

1. Ausbacher, D.; G. Svineng, T. Hansen, and M.B. Strøm. 2012. Anticancer mechanisms of action of two small amphipathic β(2,2)-amino acid derivatives derived from antimicrobial peptides. Biochimica et Biophysica Acta 1818: 2917-2925.
2. Carver, T.; and A. Bleasby. 2003. The design of Jemboss: A graphical user interface to EMBOSS. Bioinformatics 19: 1837-1843.
3. Chen, Y.; M.T. Guarnieri, A.I. Vasil, M.L. Vasil, C.T. Mant, and R.S. Hodges. 2007. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrobial Agents and Chemotherapy 51: 1398-1406.
4. Chen, Y.; C.T. Mant, and R.S. Hodges. 2002. Determination of stereochemistry stability coefficients of amino acid side-chains in an amphipathic alpha-helix. Journal of Peptide Research 59: 18-33.
5. Chen, Y.; A.I. Vasil, L. Rehaume, C.T. Mant, J.L. Burns, M.L. Vasil, R.E. Hancock, and R.S. Hodges. 2006. Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chemical Biology & Drug Design 67: 162-173.
6. Dathe, M.; T. Wieprecht, H. Nikolenko, L. Handel, W.L. Maloy, D.L. MacDonald, M. Beyermann, and M. Bienert. 1997. Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Letters 403: 208-212.
7. Eisenberg, D.; R.M. Weiss, and T.C. Terwilliger. 1982. The helical hydrophobic moment: A measure of the amphiphilicity of a helix. Nature 299: 371-374.
8. Hancock, R.E.; and H.G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology 24: 1551-1557.
9. Hoskin, D.W.; and A. Ramamoorthy. 2008. Studies on anticancer activities of antimicrobial peptides. Biochimica et Biophysica Acta 1778: 357-375.
10. Huang, Y.B.; X.F. Wang, H.Y. Wang, Y. Liu, and Y. Chen. 2011. Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. Molecular Cancer Therapeutics 10: 416-426.
11. Jemal, A.; R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, and M.J. Thun. 2006. Cancer statistics. CA: A Cancer Journal for Clinicians 56: 106-130.
12. Jenssen, H.; P. Hamill, and R.E. Hancock. 2006. Peptide antimicrobial agents. Clinical Microbiology Reviews 19: 491-511.
13. Jiang, Z.; A.I. Vasil, L. Gera, M.L. Vasil, and R.S. Hodges. 2011. Rational design of α-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: Utilization of charge, 'specificity determinants', total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chemical Biology & Drug Design 77: 225-240.
14. Kovacs, J.M.; C.T. Mant, and R.S. Hodges. 2006. Determination of intrinsic hydrophilicity/hydrophobicity of amino acid side chains in peptides in the absence of nearest-neighbor or conformational effects. Biopolymers 84: 283-297.
15. Leuschner, C.; and W. Hansel. 2004. Membrane disrupting lytic peptides for cancer treatments. Current Pharmaceutical Design 10: 2299-2310.
16. Mader, J.S.; and D.W. Hoskin. 2006. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opinion on Investigational Drugs 15: 933-946.
17. Mant, C.T.; J.M. Kovacs, H.M. Kim, D.D. Pollock, and R.S. Hodges. 2009. Intrinsic amino acid side-chain hydrophilicity/hydrophobicity coefficients determined by reversed-phase high-performance liquid chromatography of model peptides: Comparison with other hydrophilicity/hydrophobicity scales. Biopolymers 92: 573-595.
18. Papo, N.; Z. Oren, U. Pag, H.G. Sahl, and Y. Shai. 2002. The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. Journal of Biological Chemistry 277: 33913-33921.
19. Papo, N.; M. Shahar, L. Eisenbach, and Y. Shai. 2003. A novel lytic peptide composed of dl-amino acids selectively kills cancer cells in culture and in mice. Journal of Biological Chemistry 278: 21018-21023.
20. Paredes-Gamero, E.J.; M.N. Martins, F.A. Cappabianco, J.S. Ide, and A. Miranda. 2012. Characterization of dual effects induced by antimicrobial peptides: Regulated cell death or membrane disruption. Biochimica et Biophysica Acta 1820: 1062-1072.
21. Shadidi, M.; and M. Sioud. 2003. Selective targeting of cancer cells using synthetic peptides. Drug Resistance Updates 6: 363-371.
22. Shai, Y. 1999. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochimica et Biophysica Acta 1462: 55-70.
23. Shang, D.; F. Yu, J. Li, J. Zheng, L. Zhang, and Y. Li. 2009. Molecular cloning of cDNAs encoding antimicrobial peptide precursors from the skin of the Chinese brown frog, Rana chensinensis. Zoological Science 26: 220-226.
24. Smith, L.L.; K. Brown, P. Carthew, C.K. Lim, E.A. Martin, J. Styles, and I.N. White. 2000. Chemoprevention of breast cancer by tamoxifen: Risks and opportunities. Critical Reviews in Toxicology 30: 571-594.
25. Stark, M.; L.P. Liu, and C.M. Deber. 2002. Cationic hydrophobic peptides with antimicrobial activity. Antimicrobial Agents and Chemotherapy 46: 3585-3590.
26. Szakács, G.; J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman. 2006. Targeting multidrug resistance in cancer. National Reviews. Drug Discovery. 5: 219-234.
27. Wang, C.; H.B. Li, S. Li, L.L. Tian, and D.J. Shang. 2012. Antitumor effects and cell selectivity of temporin-1CEa, an antimicrobial peptide from the skin secretions of the Chinese brown frog (Rana chensinensis). Biochimie 94: 434-441.
28. Wieprecht, T.; M. Dathe, M. Beyermann, E. Krause, W.L. Maloy, D.L. MacDonald, and M. Bienert. 1997. Peptide hydrophobicity controls the activity and selectivity of magainin 2 amide in interaction with membranes. Biochemistry 36: 6124-6132.
29. Yeaman, M.R.; and N.Y. Yount. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacological Reviews 55: 27-55.